Full history for every metric is available with a Kvantra account
Salarius Pharmaceuticals, Inc. (SLRX)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -13 | -15 | |||||
| Net profit | $m | -7 | -13 | -32 | -13 | -6 | -13 | -14 |
| EPS reported | $ | -25.99 | -30.00 | |||||
| Operating cashflow per share | $ | -10.02 | -17.29 | |||||
| Capex per share | $ | 0.00 | 0.09 | |||||
| FCF per share | $ | -10.02 | -17.37 | |||||
| Free cash flow | $m | -5 | -8 | |||||
| Net debt | $m | -11 | -8 | |||||
| Book value equity | $m | 6 | 4 | |||||
| Book value per share | $ | 12.23 | 8.97 | |||||
| Number of shares | m | 0.48 | 0.48 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.05 | 1.14 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.06 | -0.59 | |||||
| EV/EBITDA LTM | x | -1,453.99 | 0.96 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -4006.5% | -3571.9% | |||||
| FCF Yield | % | -1544.9% | -169.91% | |||||
| Quality | ||||||||
| ROE | % | -212.58% | -315.23% | |||||
| ROIC | % | -214.20% | -344.44% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | -1,497.68 | 2.37 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -3427.7% | -168.33% | |||||
| Net debt/Equity | x | -1.82 | -1.92 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to advancing epigenetic-based cancer therapies. Its flagship investigational product, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical evaluation. This compound is being developed to treat Ewing sarcoma and a range of advanced solid tumors. Another promising program involves SP-3164, a small molecule protein degrader designed to target both hematological and solid malignancies. The company has cultivated several key alliances. These include an exclusive licensing agreement with The University of Utah Research Foundation for the intellectual property associated with SP-2577 and related compounds. A collaboration with HLB Life Sciences grants rights for the comprehensive development, production, and commercialization of the drug in South Korea. Furthermore, Salarius partners with the Cancer Prevention and Research Institute of Texas (CPRIT) to accelerate product development activities. A research collaboration with the Cancer Epigenetics Institute at Fox Chase Cancer Center aims to uncover new indications and biomarkers for SP-2577. Corporate operations are managed from its headquarters in Houston, Texas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Salarius Pharmaceuticals, Inc. (SLRX)
Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to advancing epigenetic-based cancer therapies. Its flagship investigational product, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical evaluation. This compound is being developed to treat Ewing sarcoma and a range of advanced solid tumors. Another promising program involves SP-3164, a small molecule protein degrader designed to target both hematological and solid malignancies. The company has cultivated several key alliances. These include an exclusive licensing agreement with The University of Utah Research Foundation for the intellectual property associated with SP-2577 and related compounds. A collaboration with HLB Life Sciences grants rights for the comprehensive development, production, and commercialization of the drug in South Korea. Furthermore, Salarius partners with the Cancer Prevention and Research Institute of Texas (CPRIT) to accelerate product development activities. A research collaboration with the Cancer Epigenetics Institute at Fox Chase Cancer Center aims to uncover new indications and biomarkers for SP-2577. Corporate operations are managed from its headquarters in Houston, Texas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free